Biogen reported positive Phase 2/3 DEVOTE study results for high dose nusinersen in spinal muscular atrophy, published in ...

Biogen (NasdaqGS:BIIB) received Breakthrough Therapy Designation from the FDA for litifilimab in cutaneous lupus ...

Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both ...

Biogen Inc. (BIIB) stock reached a 52-week high, peaking at 190.34 USD, underscoring a robust performance over the past year. The stock has experienced a notable 31.14% increase over the last 12 ...

V2X, Inc., , a leading provider of global mission solutions, will report fourth quarter and full year 2025 financial results on Monday, February 23, 2026, after market close. Senior management will ...

("Kneat" or the "Company"), a leader in digitizing and automating validation and quality processes, announced today that the Company will release its financial results for the quarter ended December ...

Biogen's "growth products" — about a half-dozen products including Leqembi — contributed $800 million to the firm's $2.28 ...

Treatment with a high-dose regimen of Spinraza safely improved motor function in children with SMA, according to data from ...

St. Mary's University's Jada Cano plans to try out for the U.S. National Power Soccer team for a chance to compete in the world cup.

For the full-year 2024, Biogen revenues amounted to $9.7bn, down 2% year-on-year, while GAAP diluted EPS was up 40%, to $11.21, and non-GAAP EPS $16.47, up 12% year-on-year. In terms of guidance for ...

Precedence Research, a leading strategic research firm, today released a comprehensive overview of the gene therapy and ...